No Data
No Data
Alkermes (ALKS) Down 0.2% Since Last Earnings Report: Can It Rebound?
Alkermes Launches Phase II Trial of ALKS 2680 for Narcolepsy Type 2
Express News | Alkermes PLC - Vibrance-1 Study for Narcolepsy Type 1 Currently Enrolling
Express News | Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating Alks 2680 for the Treatment of Narcolepsy Type 2
Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2
We Ran A Stock Scan For Earnings Growth And Alkermes (NASDAQ:ALKS) Passed With Ease
No Data